Abstract
Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Annals of Oncology |
Vol/bind | 21 |
Udgave nummer | 9 |
Sider (fra-til) | 1817-24 |
Antal sider | 8 |
ISSN | 0923-7534 |
DOI | |
Status | Udgivet - 1 sep. 2010 |